Congruence Therapeutics has completed a $32m funding round, earmarked for propelling its genetic obesity drug, CGX-926, into a Phase Ib proof of concept study.<\/p>\n
The funding has been supported by various current investors, including FSTQ, Amplitude Ventures, Lumira, BDC Capital’s Thrive Venture Fund, Investissement Quebec, OrbiMed, Silver Arc, Alexandria, and Driehaus.<\/p>\n
Congruence noted that CGX-926 is the initial clinical candidate that addresses melanocortin 4 receptor-deficient (MC4R-d) genetic obesity.<\/p>\n
The company has outlined plans to initiate a Phase I study involving healthy volunteers and subsequently, the Phase Ib efficacy cohort targeting individuals with MC4R-d, with the trials expected to commence in early 2026.<\/p>\n
Congruence anticipates filing the clinical trial application in the second half of this year.<\/p>\n
Beyond the development of CGX-926, Congruence is also setting its sights on progressing its therapeutic programmes for Parkinson’s disease and alpha-1 antitrypsin (A1AT) deficiency into the advanced stages of preclinical testing.<\/p>\n
In addition to these developments, the company is moving forward with its research and development collaborations.<\/p>\n
These include a multi-target oncology agreement with Ono Pharmaceuticals and a partnership focused on a challenging metabolic target with an unnamed pharma company.<\/p>\n
Central to Congruence’s innovation is its computational drug discovery platform, Revenir, designed to detect the biophysical alterations caused by protein mutations, thereby providing insights into protein malfunctions and methods for their rectification.<\/p>\n
Revenir operates by analysing surface characteristics and a range of biophysical descriptors within a collection of protein conformers, thereby forecasting the potential for small molecules to rectify the pathogenic defects in proteins.<\/p>\n
Leveraging its discovery engine, Congruence has initiated a portfolio of fully owned drugs aimed at genetically validated targets.<\/p>\n
These targets span across multiple indications, including GBA Parkinson’s disease, genetic obesity and \u03b11-antitrypsin deficiency.<\/p>\n
Congruence Therapeutics CEO Dr Clarissa Desjardins said: “This financing enables us to generate the first clinical proof of concept data with our corrector for MC4R-d driven obesity, a serious and debilitating condition without current treatment options.<\/p>\n
\u201cWe will also advance our programmes in GBA-1 Parkinson’s disease and alpha-1 antitrypsin deficiency toward development candidate nomination this year.”<\/p>\n